Pasiniazid
Pasiniazid structure
|
Common Name | Pasiniazid | ||
|---|---|---|---|---|
| CAS Number | 2066-89-9 | Molecular Weight | 290.27500 | |
| Density | N/A | Boiling Point | 380.8ºC at 760 mmHg | |
| Molecular Formula | C13H14N4O4 | Melting Point | 142-144° | |
| MSDS | Chinese USA | Flash Point | 184.1ºC | |
| Symbol |
GHS07 |
Signal Word | Warning | |
Use of PasiniazidPasiniazid is an anti-TB and anti-leprosy drug, used to treat various types of TB and leprosy. |
| Name | 4-amino-2-hydroxybenzoic acid,pyridine-4-carbohydrazide |
|---|---|
| Synonym | More Synonyms |
| Description | Pasiniazid is an anti-TB and anti-leprosy drug, used to treat various types of TB and leprosy. |
|---|---|
| Related Catalog |
| Boiling Point | 380.8ºC at 760 mmHg |
|---|---|
| Melting Point | 142-144° |
| Molecular Formula | C13H14N4O4 |
| Molecular Weight | 290.27500 |
| Flash Point | 184.1ºC |
| Exact Mass | 290.10200 |
| PSA | 151.56000 |
| LogP | 2.03010 |
| Vapour Pressure | 1.78E-06mmHg at 25°C |
| InChIKey | RKPHTRVPGYGVQD-UHFFFAOYSA-N |
| SMILES | NNC(=O)c1ccncc1.Nc1ccc(C(=O)O)c(O)c1 |
| Storage condition | 2-8℃ |
| Symbol |
GHS07 |
|---|---|
| Signal Word | Warning |
| Hazard Statements | H302-H315-H319-H335 |
| Precautionary Statements | P261-P305 + P351 + P338 |
| Personal Protective Equipment | dust mask type N95 (US);Eyeshields;Gloves |
| Hazard Codes | Xi: Irritant; |
| Risk Phrases | R22;R36/37/38 |
| Safety Phrases | S26-S36/37 |
| RIDADR | NONH for all modes of transport |
| WGK Germany | 3 |
| HS Code | 2933399090 |
|
~%
Pasiniazid CAS#:2066-89-9 |
| Literature: CrystEngComm, , vol. 13, # 13 p. 4358 - 4364 |
| HS Code | 2933399090 |
|---|---|
| Summary | 2933399090. other compounds containing an unfused pyridine ring (whether or not hydrogenated) in the structure. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0% |
|
[Short-term effect of treatment protocol utilizing levofloxacin, pasiniazide and M. Vaccae on multi- drug resistant pulmonary tuberculosis].
Di Yi Jun Yi Da Xue Xue Bao 24(5) , 574-5, 578, (2004) To observe the effects of the protocol combining levofloxacin, pasiniazide, M. Vaccae (V+D+M protocol) in the treatment of multi-drug resistant pulmonary tuberculosis (MDR-TB).Ninety-seven cases of MD... |
|
|
[Clinical research of pasinizid on retreated sputum positive pulmonary tuberculosis in senilities].
Zhonghua Jie He He Hu Xi Za Zhi 24(10) , 608-10, (2001) To observe and evaluate the effect and safety of pasinizid on treatment of the senile pulmonary tuberculosis with bacteriological positive.115 cases of the senile pulmonary tuberculosis with bacteriol... |
|
|
A reproducible, simple, and sensitive high-performance capillary electrophoresis method for simultaneous determination of capreomycin, ofloxacin and pasiniazide in urine.
J. Pharm. Biomed. Anal. 17(4-5) , 617-22, (1998) Separation and determination of capreomycin (Cp), ofloxacin (Oflx) and pasiniazide (Ipa) in urine by high-performance capillary electrophoresis (HPCE) with 280 nm detection have been studied systemati... |
| Pasiniazid |
| Aminosalicylic acid mixture with Isoniazid |
| Isonicotinsaeure-hydrazid,4-Amino-2-hydroxy-benzoat |
| isonicotinic acid hydrazid,4-amino-2-hydroxy benzoate |
| Pasiniazide |
| Pasiniazid [INN:DCF] |
| Isoniazid 4-aminosalicylate |
| Isonicotinsaeurehydrazid-p-aminosalicylat |
| Pasiniazida |
| Pasiniazidum |